Johnson & Johnson (JNJ) $240.45
J&J currently navigates a tight range, with its stock price hovering near recent highs, yet imminent earnings create a palpable tension. This healthcare giant’s technical setup points to strength, but investors face a critical decision point before the next report.
52-wk High $251.71
📌 Investment Snapshot
- 💰 JNJ trades at $240.45, with a $579.5B market cap and a P/E of 21.8x.
- 📈 Q4 2025 revenue hit $24.56B, with EPS at $2.08.
- 🔑 Strong technical confluence (90/100) suggests underlying buying interest.
- 🎯 Analysts maintain a ‘Buy’ consensus with a mean target of $241.08, offering minimal immediate upside.
JNJ’s current price sits just above its 50-day SMA, indicating short-term strength, yet the RSI remains neutral at 44.7 and earnings are due within days. This combination signals a period of heightened uncertainty, warranting caution despite robust technicals.
| 📍 Entry Zone | $236.00 or below | 🛑 Stop-Loss | $230.00 |
| 📋 Adjust If | Price breaks above $245.00 on strong volume, confirming a push past recent resistance. | ||
The Investment Case — Why Now?
Over the past three months, JNJ has seen a significant 16.4% rally, pushing it near its 52-week high. This upward momentum, supported by consistent quarterly revenues and strategic buybacks, reflects investor confidence in its diversified healthcare portfolio.
However, the stock now trades with minimal upside to the consensus target and faces imminent Q1 2026 earnings, which could introduce volatility. The high VIX at 31.05 also suggests a market prone to sharp moves, making pre-earnings entry a higher-risk proposition.
🤔 Given the strong 3-month rally, are current valuations already pricing in J&J’s near-term growth, or does the upcoming earnings report hold potential for a significant surprise?
🏢 Company Overview
| Detail | Value |
|---|---|
| Company | Johnson & Johnson |
| Ticker / Exchange | JNJ / NYSE |
| Sector / Industry | Healthcare / Drug Manufacturers – General |
| CEO | Joaquin Duato |
| Founded / HQ | 1886 / New Brunswick, New Jersey, USA |
📈 Price Action & Technicals
Inside VA
A buy-side sweep at $240.30 on March 26, 2026, suggests immediate demand at current levels.
JNJ currently trades above its 50-day SMA of $236.27, signaling short-term bullishness, while maintaining a significant premium over its 200-day SMA at $194.83. This wide separation underscores the stock’s strong upward trend over the past year.
The RSI at 44.7 indicates neutral momentum, neither overbought nor oversold, suggesting the recent rally may be consolidating. MACD shows a slight bearish divergence with its value (0.22) below the signal line (0.9), hinting at potential weakening momentum. ADX at 23.4, with -DI (20.4) slightly above +DI (16.0), confirms a lack of strong trend direction in the immediate term.
Price action remains within the Value Area ($159.88-$247.72), although near its upper bound, indicating fair value acceptance around these levels. The Anchored VWAP from May 2025 at $191.42 sits well below the current price, reinforcing the long-term bullish sentiment and institutional accumulation.
Recent buy-side liquidity sweeps at $240.30 and $235.43 confirm institutional interest in defending these price points. However, volume running at 98% of its 20-day average suggests a lack of conviction for a decisive breakout without a fresh catalyst.
🤔 With JNJ’s price sitting near the top of its Value Area and MACD showing a bearish cross, does the recent institutional buying signal a floor, or merely a temporary pause before a deeper correction?
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| JNJ | Johnson & Johnson | 21.8x |
| PFE | Pfizer Inc. | 15.5x |
| MRK | Merck & Co., Inc. | 25.1x |
| LLY | Eli Lilly and Company | 40.3x |
| S&P 500 | Index Average | 21.0x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 2025 | $24.56B | $2.08 | +2.4% |
| Q3 2025 | $23.99B | $2.12 | +3.1% |
| Q2 2025 | $23.74B | $2.29 | +4.3% |
| Q1 2025 | $21.89B | $4.54 | +5.2% |
J&J generated a robust Free Cash Flow of $5.5B in the latest quarter, demonstrating strong operational efficiency. The company actively returned capital to shareholders through share buybacks totaling $1.9B, alongside its consistent dividend payments.
🚀 Growth Drivers — What Moves the Stock
- Pharmaceutical Pipeline Strength 🟢 Upside Surprise — J&J’s diversified pharmaceutical segment continues to drive growth with several blockbuster drugs and a robust pipeline. New approvals and expanded indications for key therapies like Darzalex and Stelara are expected to fuel future revenue, particularly in oncology and immunology.
- MedTech Innovation 🟢 Upside Surprise — The MedTech segment benefits from innovation in surgical technologies and interventional solutions. Strategic acquisitions and product launches, such as advanced robotic-assisted surgery platforms, position J&J for market share gains in a growing sector.
- Consumer Health Spin-off (Kenvue) 🟡 Priced In — The successful spin-off of Kenvue has allowed J&J to focus entirely on its higher-margin Pharmaceutical and MedTech businesses. This strategic streamlining is expected to enhance profitability and capital allocation efficiency for the remaining entity.
🤔 With the Kenvue spin-off now complete, how much further upside can J&J extract from its focused pharma and medtech segments, especially considering the competitive landscape?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Vanguard Group Inc | 240,349 |
| Blackrock Inc. | 208,781 |
| State Street Corporation | 133,869 |
| JPMORGAN CHASE & CO | 58,558 |
| Geode Capital Management, LLC | 57,953 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| WOLK JOSEPH J | Chief Financial Officer | Feb 17, 2026 | Sale | 89,654 |
| SWANSON JAMES D | Chief Technology Officer | Feb 17, 2026 | Sale | 62,080 |
| BROADHURST VANESSA | Officer | Feb 17, 2026 | Sale | 6,197 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 0.0% | 2.7 |
⚠ Key Risk Factors
~5-10% price swing
~$XB impact
~$X.XB revenue loss
~0-5% upside cap
🎯 Guidance & Wall Street View
Management has maintained a cautious yet confident outlook for 2026, emphasizing continued investment in R&D and strategic portfolio optimization. They project mid-single-digit revenue growth driven by key pharmaceutical and MedTech innovations.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $280.0 | $241.08 | $155.0 | 24 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Barclays | Equal-Weight | Mar 2026 | Maintains | |
| HSBC | Buy | Mar 2026 | Maintains | |
| Citigroup | Buy | Mar 2026 | Maintains | |
| JP Morgan | Neutral | Mar 2026 | Maintains | |
| RBC Capital | Outperform | Feb 2026 | Maintains |
The analyst consensus of ‘Buy’ reflects long-term confidence in J&J’s diversified business model, despite the minimal upside to the mean target. The range from $155 to $280 indicates a wide divergence in individual firm outlooks.
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Strong pharmaceutical pipeline delivers multiple blockbuster drugs, exceeding market expectations for growth.
- Successful integration of MedTech innovations and strategic acquisitions drives market share expansion and margin improvement.
📊 Base Case
Our base case assumes J&J continues its steady, diversified growth, driven by its core pharma and MedTech segments. We anticipate modest revenue increases and consistent profitability, largely in line with current analyst expectations, with the stock trading near its fair value.
🐻 Bear Case
- Unexpected setbacks in clinical trials or increased litigation risks lead to significant financial penalties and reputational damage.
- Aggressive biosimilar competition and patent cliffs impact revenue more severely than anticipated, forcing downward revisions to guidance.
🎯 Investor Action Plan — By Profile
Swing traders should avoid JNJ pre-earnings due to high volatility risk. Wait for a clear post-earnings trend confirmation, ideally a break above $245 with strong volume, before considering any short-term positions.
Position investors should stay on the sidelines until after the Q1 earnings report. A potential entry window could open if the stock pulls back towards the $236.00-$238.93 FVG zone or the 50-day SMA post-earnings.
Long-term investors already holding JNJ should maintain their position, as the fundamental thesis of a diversified healthcare leader remains intact. Consider adding on any significant post-earnings dips towards the $220-$230 range, which aligns with deeper FVG zones.
❓ Investor FAQ — People Also Ask
Q: Why is the verdict ‘WAIT’ despite a strong technical confluence score?
While JNJ boasts a strong technical confluence score of 90/100, indicating robust underlying support, the RSI is neutral (44.7) and the stock offers minimal upside to its consensus target (0.26%). Crucially, Q1 earnings are imminent, creating significant uncertainty that outweighs the positive technical signals for immediate entry.
Q: What are the key support levels to watch for JNJ?
Investors should monitor the 50-day SMA at $236.27 as immediate support. Below that, the bullish FVG zone between $236.00 and $238.93 and deeper FVG zones around $227-$231 offer potential buying opportunities if the stock experiences a post-earnings pullback.
Q: How do institutional holdings and insider transactions factor into the analysis?
Institutional ownership is substantial, with major players like Vanguard and Blackrock holding significant stakes, signaling long-term confidence. However, recent insider sales by multiple officers, while often routine, warrant attention as they can sometimes precede periods of consolidation or weakness.
📊 Want to verify if this analysis still holds?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.
All active positions and their real-time performance are tracked on our Investment Log.
#JNJ #JohnsonAndJohnson #HealthcareStocks #StockAnalysis #NYSE #Pharma #MedTech #DividendStocks